Trial Profile
A Single Arm, Phase II Open Label Trial to Investigate the Efficacy and Safety of Intra-dermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Discoid lupus erythematosus
- Focus Therapeutic Use
- Acronyms TARGET-DLE
- 16 Jun 2018 Status changed to completed as per results presented at the 19th Annual Congress of the European League Against Rheumatism
- 16 Jun 2018 Primary endpoint has been met. (The proportion of patients who achieve a reduction in the modified limited Score of Activity and Damage in Discoid Lupus Erythematosus (SADDLE) score by 20% of the baseline score in the index lesion) as per results presented at the 19th Annual Congress of the European League Against Rheumatism
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism